<div class="infobox infobox-company">
Overview
flowchart TD
companies_iduna_biotechnology["Iduna Biotechnology"]
companies_iduna_biotechnology_["infobox-company"]
companies_iduna_biotechnology -->|"related to"| companies_iduna_biotechnology_
style companies_iduna_biotechnology_ fill:#81c784,stroke:#333,color:#000
companies_iduna_biotechnology_["infobox-header"]
companies_iduna_biotechnology -->|"related to"| companies_iduna_biotechnology_
style companies_iduna_biotechnology_ fill:#81c784,stroke:#333,color:#000
companies_iduna_biotechnology_["infobox-row"]
companies_iduna_biotechnology -->|"related to"| companies_iduna_biotechnology_
style companies_iduna_biotechnology_ fill:#81c784,stroke:#333,color:#000
companies_iduna_biotechnology_["strong"]
companies_iduna_biotechnology -->|"related to"| companies_iduna_biotechnology_
style companies_iduna_biotechnology_ fill:#81c784,stroke:#333,color:#000
style companies_iduna_biotechnology fill:#4fc3f7,stroke:#333,color:#000
... <div class="infobox infobox-company">
Overview
Mermaid diagram (expand to render)
Iduna Biotechnology is a biotechnology company developing small molecule therapeutics that enhance chaperone-mediated autophagy (CMA) for the treatment of Parkinson's disease and related neurodegenerative disorders. The company's name references Iduna, the Norse goddess associated with apples of youth and rejuvenation, reflecting its mission to restore cellular homeostasis and prevent neurodegeneration["@iduna_corp"].
Iduna's approach targets LAMP2A (lysosome-associated membrane protein 2A), the rate-limiting receptor for CMA, which is specifically impaired in Parkinson's disease. The company has identified small molecule activators of LAMP2A that can restore CMA function and promote clearance of toxic [alpha-synuclein](/proteins/alpha-synuclein) aggregates.
Scientific Rationale
CMA is a selective autophagy pathway that degrades cytosolic proteins through direct translocation across the lysosomal membrane. LAMP2A forms multimeric translocation complexes that recognize and import CMA substrates[@lamp2a_cma].
Key findings in PD:
LAMP2A expression is reduced in [substantia nigra](/cell-types/substantia-nigra-compacta) of PD patients[@koga2018]
[Alpha-synuclein](/proteins/alpha-synuclein) is a CMA substrate — mutant forms accumulate when CMA is impaired
Loss of CMA function leads to accumulation of toxic protein aggregates
Restoring CMA enhances clearance of pathogenic alpha-synuclein species[@martinez2017]
Therapeutic Approach Iduna develops LAMP2A agonists that:
Increase LAMP2A clustering on lysosomal membranes
Enhance substrate binding and translocation
Promote clearance of misfolded proteins
Protect dopaminergic neurons from degeneration
Pipeline | Drug | Mechanism | Phase | Indication |
IDU-101 (Lead Program)
Mechanism : Small molecule LAMP2A agonistTarget : LAMP2A receptor on lysosomesRoute : OralStatus : IND-enabling studiesIndication : Early-stage Parkinson's diseaseResearch Highlights Iduna's platform has demonstrated:
Increased LAMP2A clustering in neurons exposed to IDU-101
Enhanced alpha-synuclein clearance in cellular models
Neuroprotection in MPTP mouse models of PD
Blood-brain barrier penetration in rodent studies
High-Throughput Screening Iduna uses a proprietary cell-based screening platform to identify LAMP2A modulators:
Fluorescent reporter for CMA activity
Primary neuron validation
Alpha-synuclein clearance assays
Lead optimization for brain penetration
Target Validation The company has validated LAMP2A as a therapeutic target through:
Genetic studies showing LAMP2A knockdown increases alpha-synuclein toxicity
Patient-derived neurons showing reduced CMA activity
Post-mortem brain tissue showing decreased LAMP2A in PD
Competitive Landscape | Company | Target | Approach | Status |
Funding
Seed : $3M (2020)Series A : $15M (2022) — led by ARCH Venture PartnersTotal raised : $18MScientific Advisory Board Iduna has assembled leading experts in autophagy and neurodegeneration:
Dr. David Sulzer (Columbia University) — CMA in PD
Dr. Maria Martinez (Universidad Autonoma de Madrid) — LAMP2A biology
Dr. Timothy Greenamyre (University of Pittsburgh) — PD mechanisms
References
[Iduna Biotechnology Corporate Website](https://www.idunabio.com)
[Chaperone-mediated autophagy in Parkinson's disease: LAMP2A as therapeutic target, Nat Rev Neurol (2022)](https://doi.org/10.1038/s41582-022-00645-x)
[Koga H, et al. LAMP2A regulates alpha-synuclein clearance in neurons, Nat Neurosci (2018)](https://doi.org/10.1038/s41593-018-0234-5)
[Martinez A, et al. Chaperone-mediated autophagy dysfunction in Parkinson's disease, J Neurosci (2017)](https://pubmed.ncbi.nlm.nih.gov/28972151/)
See Also
[Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy-neurodegeneration)
[LAMP2A Protein](/proteins/lamp2a-protein)
[Autophagy Enhancement](/therapeutics/autophagy-enhancers-pd)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)
Pathway Diagram The following diagram shows the key molecular relationships involving Iduna Biotechnology discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Show full description